Sanofi Scouting For Cancer Deals, Diabetes Drugs Miss In 1Q

Sanofi is seeking asset deals to bulk up its oncology pipeline in 2017 – specifically, the big pharma is on the lookout for oncology compounds with potential in prostate cancer or breast cancer, the company highlighted during its first-quarter earnings call.

Handshake of businessmen
M&A action could change Sanofi's story in 2017

Sanofi's diabetes and cardiovascular products drastically missed their sales targets in the first quarter of the year – but the company has high hopes for its R&D pipeline this year and the spotlight is on oncology.

The French drug maker also highlighted during its April 28 earnings conference call that it is seeking asset acquisitions in...

More from Deals

More from Business